Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanya B Dorff

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
PARP inhibition in HRR gene-mutated metastatic castration-resistant prostate cancerTanya B Dorff
European Journal of Cancer (Oxford, England : 1990)|April 6, 2005
Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapyJacek Pinski, Tanya B Dorff
Translational Andrology and Urology|August 25, 2021
Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patientsYung Lyou, Tanya B Dorff
Oncology (Williston Park, N.Y.)|July 2, 2011
Advanced prostate cancer: new agents, new questionsTanya B Dorff, Jacek Pinski
Asian Journal of Andrology|March 20, 2018
Bone-targeted therapies to reduce skeletal morbidity in prostate cancerTanya B Dorff, Neeraj Agarwal
Cancer|August 1, 2009
Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor?Tanya B Dorff, David I Quinn
JCO Precision Oncology|January 31, 2025
Leveraging Artificial Intelligence to Improve Risk Stratification in Nonmetastatic Castration-Resistant Prostate CancerCharles B Nguyen, Tanya B Dorff
Oncology (Williston Park, N.Y.)|June 21, 2015
Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous MetastasesTanya B Dorff, Sumanta K Pal
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
IDO Believe in ImmunotherapyPeter D Zang, Tanya B Dorff
European Urology|August 9, 2022
A Path to Precision Medicine in Prostate Cancer: Learning from "Negative" Trials of Targeted TherapiesTanya B Dorff, Alicia K Morgans
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
PARP inhibition in HRR gene-mutated metastatic castration-resistant prostate cancerTanya B Dorff
European Journal of Cancer (Oxford, England : 1990)|April 6, 2005
Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapyJacek Pinski, Tanya B Dorff
Translational Andrology and Urology|August 25, 2021
Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patientsYung Lyou, Tanya B Dorff
Oncology (Williston Park, N.Y.)|July 2, 2011
Advanced prostate cancer: new agents, new questionsTanya B Dorff, Jacek Pinski
Asian Journal of Andrology|March 20, 2018
Bone-targeted therapies to reduce skeletal morbidity in prostate cancerTanya B Dorff, Neeraj Agarwal
Cancer|August 1, 2009
Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor?Tanya B Dorff, David I Quinn
JCO Precision Oncology|January 31, 2025
Leveraging Artificial Intelligence to Improve Risk Stratification in Nonmetastatic Castration-Resistant Prostate CancerCharles B Nguyen, Tanya B Dorff
Oncology (Williston Park, N.Y.)|June 21, 2015
Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous MetastasesTanya B Dorff, Sumanta K Pal
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
IDO Believe in ImmunotherapyPeter D Zang, Tanya B Dorff
European Urology|August 9, 2022
A Path to Precision Medicine in Prostate Cancer: Learning from "Negative" Trials of Targeted TherapiesTanya B Dorff, Alicia K Morgans
Pageof 13